Symbols / NSPR
NSPR Chart
About
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as well as treating acute stroke with tandem lesions. It has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Miami, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 77.96M |
| Enterprise Value | 18.36M | Income | -46.20M | Sales | 7.78M |
| Book/sh | 1.53 | Cash/sh | 1.50 | Dividend Yield | — |
| Payout | 0.00% | Employees | 66 | IPO | — |
| P/E | — | Forward P/E | -2.33 | PEG | — |
| P/S | 10.02 | P/B | 1.20 | P/C | — |
| EV/EBITDA | -0.40 | EV/Sales | 2.36 | Quick Ratio | 6.09 |
| Current Ratio | 6.51 | Debt/Eq | 5.26 | LT Debt/Eq | — |
| EPS (ttm) | -0.82 | EPS next Y | -0.79 | EPS Growth | — |
| Revenue Growth | 39.40% | Earnings | 2026-03-11 | ROA | -45.46% |
| ROE | -87.61% | ROIC | — | Gross Margin | 24.91% |
| Oper. Margin | -5.17% | Profit Margin | 0.00% | Shs Outstand | 42.37M |
| Shs Float | 19.94M | Short Float | 0.09% | Short Ratio | 0.75 |
| Short Interest | — | 52W High | 3.80 | 52W Low | 1.51 |
| Beta | 0.90 | Avg Volume | 45.43K | Volume | 19.74K |
| Target Price | $5.00 | Recom | Buy | Prev Close | $1.85 |
| Price | $1.84 | Change | -0.54% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.00
Mean price target
2. Current target
$1.84
Latest analyst target
3. DCF / Fair value
$-7.03
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.84
Low
$4.00
High
$6.00
Mean
$5.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-05-12 | main | Piper Sandler | Overweight → Overweight | $4 |
| 2024-12-11 | init | Lake Street | — → Buy | $5 |
| 2023-11-02 | main | Piper Sandler | Overweight → Overweight | $5 |
| 2023-06-12 | init | Piper Sandler | — → Overweight | $3 |
| 2023-05-17 | main | National Alliance Securities | — → Buy | $5 |
| 2023-03-31 | main | Alliance Global Partners | — → Buy | $5 |
- Lake Street reiterates InspireMD stock rating citing market growth By Investing.com - Investing.com Nigeria Wed, 25 Feb 2026 06
- Aberdeen Group plc Makes New Investment in InspireMD, Inc. $NSPR - MarketBeat Sat, 21 Feb 2026 08
- InspireMD (NASDAQ:NSPR) shareholders have endured a 81% loss from investing in the stock five years ago - Yahoo Finance Sat, 10 Jan 2026 08
- InspireMD (Nasdaq: NSPR) grants 122,054 inducement shares to eight new hires - Stock Titan Fri, 21 Nov 2025 08
- InspireMD (NYSE:NSPR) Stock Price Down 1.8% - Should You Sell? - MarketBeat Fri, 30 Jan 2026 08
- InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance ue, 04 Nov 2025 08
- NSPR Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 00
- Shane Thomas Gleason Sells 12,395 Shares of InspireMD (NYSE:NSPR) Stock - MarketBeat Mon, 02 Feb 2026 08
- Is InspireMD (NASDAQ:NSPR) In A Good Position To Invest In Growth? - Yahoo Finance hu, 27 Nov 2025 08
- Shane Thomas Gleason Sells 17,593 Shares of InspireMD (NYSE:NSPR) Stock - MarketBeat Mon, 02 Feb 2026 08
- What to Expect from InspireMD Inc (NSPR) Q2 2025 Earnings - Yahoo Finance Mon, 04 Aug 2025 07
- InspireMD (NYSE:NSPR) Insider Shane Thomas Gleason Sells 8,411 Shares - MarketBeat Mon, 02 Feb 2026 08
- InspireMD (NYSE:NSPR) Now Covered by Maxim Group - MarketBeat Mon, 02 Feb 2026 08
- InspireMD Appoints Dr. Peter A. Soukas as Chief Medical Officer to Advance Carotid Intervention Initiatives - Quiver Quantitative Mon, 03 Nov 2025 08
- InspireMD, Inc. Schedules Release of Second Quarter 2025 Financial Results and Conference Call - Quiver Quantitative ue, 22 Jul 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 61194 | 99331 | — | Sale at price 1.57 - 1.66 per share. | GLEASON SHANE THOMAS | Officer | — | 2026-02-02 00:00:00 | D |
| 1 | 88053 | — | — | Stock Award(Grant) at price 0.00 per share. | BERMAN MICHAEL | Director | — | 2026-01-14 00:00:00 | D |
| 2 | 44030 | — | — | Stock Award(Grant) at price 0.00 per share. | COHEN RAYMOND W | Director | — | 2026-01-14 00:00:00 | D |
| 3 | 1114792 | — | — | Stock Award(Grant) at price 0.00 per share. | SLOSMAN MARVIN | Chief Executive Officer | — | 2026-01-14 00:00:00 | D |
| 4 | 88053 | — | — | Stock Award(Grant) at price 0.00 per share. | ROUBIN GARY S | Director | — | 2026-01-14 00:00:00 | D |
| 5 | 88053 | — | — | Stock Award(Grant) at price 0.00 per share. | WARD SCOTT RAYMOND | Director | — | 2026-01-14 00:00:00 | D |
| 6 | 132076 | — | — | Stock Award(Grant) at price 0.00 per share. | STUKA PAUL | Director | — | 2026-01-14 00:00:00 | D |
| 7 | 44030 | — | — | Stock Award(Grant) at price 0.00 per share. | DEAREN DANNY L | Director | — | 2026-01-14 00:00:00 | D |
| 8 | 226695 | — | — | Stock Award(Grant) at price 0.00 per share. | LAWLESS MICHAEL A. | Chief Financial Officer | — | 2026-01-14 00:00:00 | D |
| 9 | 453390 | — | — | Stock Award(Grant) at price 0.00 per share. | GLEASON SHANE THOMAS | Officer | — | 2026-01-14 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -33.22M | -20.91M | -18.52M | -14.55M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -32.01M | -19.92M | -18.49M | -14.92M |
| ReconciledDepreciation | 280.00K | 232.00K | 188.00K | 161.00K |
| ReconciledCostOfRevenue | 5.50M | 4.40M | 4.05M | 3.74M |
| EBITDA | -33.22M | -20.91M | -18.52M | -14.55M |
| EBIT | -33.50M | -21.14M | -18.71M | -14.72M |
| NetInterestIncome | 1.56M | 1.29M | 250.00K | -157.00K |
| InterestExpense | 157.00K | |||
| InterestIncome | 1.56M | 1.29M | 250.00K | |
| NormalizedIncome | -32.01M | -19.92M | -18.49M | -14.92M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -32.01M | -19.92M | -18.49M | -14.92M |
| TotalExpenses | 40.51M | 27.35M | 23.88M | 19.21M |
| TotalOperatingIncomeAsReported | -33.50M | -21.14M | -18.71M | -14.72M |
| DilutedAverageShares | 41.93M | 24.27M | 7.87M | 7.35M |
| BasicAverageShares | 41.93M | 24.27M | 7.87M | 7.35M |
| DilutedEPS | -0.76 | -0.82 | -2.35 | -2.03 |
| BasicEPS | -0.76 | -0.82 | -2.35 | -2.03 |
| DilutedNIAvailtoComStockholders | -32.01M | -19.92M | -18.49M | -14.92M |
| NetIncomeCommonStockholders | -32.01M | -19.92M | -18.49M | -14.92M |
| NetIncome | -32.01M | -19.92M | -18.49M | -14.92M |
| NetIncomeIncludingNoncontrollingInterests | -32.01M | -19.92M | -18.49M | -14.92M |
| NetIncomeContinuousOperations | -32.01M | -19.92M | -18.49M | -14.92M |
| TaxProvision | 59.00K | 65.00K | 28.00K | 45.00K |
| PretaxIncome | -31.95M | -19.85M | -18.46M | -14.87M |
| NetNonOperatingInterestIncomeExpense | 1.56M | 1.29M | 250.00K | -157.00K |
| InterestExpenseNonOperating | 157.00K | |||
| InterestIncomeNonOperating | 1.56M | 1.29M | 250.00K | |
| OperatingIncome | -33.50M | -21.14M | -18.71M | -14.72M |
| OperatingExpense | 35.01M | 22.95M | 19.83M | 15.47M |
| ResearchAndDevelopment | 13.63M | 7.98M | 7.81M | 5.16M |
| SellingGeneralAndAdministration | 21.38M | 14.97M | 12.02M | 10.31M |
| SellingAndMarketingExpense | 6.07M | 3.87M | 3.66M | 2.91M |
| GeneralAndAdministrativeExpense | 15.31M | 11.10M | 8.36M | 7.41M |
| OtherGandA | 15.31M | 11.10M | 8.36M | 7.41M |
| GrossProfit | 1.51M | 1.81M | 1.12M | 754.00K |
| CostOfRevenue | 5.50M | 4.40M | 4.05M | 3.74M |
| TotalRevenue | 7.01M | 6.21M | 5.17M | 4.50M |
| OperatingRevenue | 7.01M | 6.21M | 5.17M | 4.50M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 26.61M | 21.84M | 8.33M | 8.30M |
| ShareIssued | 26.61M | 21.84M | 8.33M | 8.30M |
| TotalDebt | 2.34M | 1.59M | 1.61M | 1.20M |
| TangibleBookValue | 36.09M | 39.50M | 17.39M | 33.53M |
| InvestedCapital | 36.09M | 39.50M | 17.39M | 33.53M |
| WorkingCapital | 32.84M | 38.14M | 16.26M | 32.75M |
| NetTangibleAssets | 36.09M | 39.50M | 17.39M | 33.53M |
| CapitalLeaseObligations | 2.34M | 1.59M | 1.61M | 1.20M |
| CommonStockEquity | 36.09M | 39.50M | 17.39M | 33.53M |
| TotalCapitalization | 36.09M | 39.50M | 17.39M | 33.53M |
| TotalEquityGrossMinorityInterest | 36.09M | 39.50M | 17.39M | 33.53M |
| StockholdersEquity | 36.09M | 39.50M | 17.39M | 33.53M |
| RetainedEarnings | -253.51M | -221.50M | -201.59M | -183.09M |
| AdditionalPaidInCapital | 289.59M | 261.00M | 218.98M | 216.62M |
| CapitalStock | 3.00K | 2.00K | 1.00K | 1.00K |
| CommonStock | 3.00K | 2.00K | 1.00K | 1.00K |
| TotalLiabilitiesNetMinorityInterest | 10.72M | 8.14M | 7.26M | 6.18M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 3.04M | 2.12M | 2.19M | 1.83M |
| EmployeeBenefits | 1.25M | 1.08M | 995.00K | 1.05M |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 1.25M | 1.08M | 995.00K | 1.05M |
| LongTermDebtAndCapitalLeaseObligation | 1.80M | 1.04M | 1.20M | 781.00K |
| LongTermCapitalLeaseObligation | 1.80M | 1.04M | 1.20M | 781.00K |
| CurrentLiabilities | 7.68M | 6.02M | 5.07M | 4.35M |
| CurrentDebtAndCapitalLeaseObligation | 542.00K | 557.00K | 419.00K | 420.00K |
| CurrentCapitalLeaseObligation | 542.00K | 557.00K | 419.00K | 420.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.41M | 2.19M | 1.85M | 1.51M |
| PayablesAndAccruedExpenses | 3.72M | 3.27M | 2.80M | 2.42M |
| CurrentAccruedExpenses | 2.21M | 2.15M | 2.01M | 1.37M |
| Payables | 1.51M | 1.13M | 789.00K | 1.05M |
| OtherPayable | 255.00K | 190.00K | 130.00K | 155.00K |
| AccountsPayable | 1.25M | 939.00K | 659.00K | 893.00K |
| TotalAssets | 46.81M | 47.64M | 24.65M | 39.71M |
| TotalNonCurrentAssets | 6.29M | 3.48M | 3.33M | 2.62M |
| DefinedPensionBenefit | 1.13M | 951.00K | 856.00K | 905.00K |
| NonCurrentPrepaidAssets | 426.00K | 0.00 | ||
| NetPPE | 4.73M | 2.53M | 2.47M | 1.71M |
| AccumulatedDepreciation | -2.32M | -2.04M | -1.91M | -1.73M |
| GrossPPE | 7.05M | 4.57M | 4.38M | 3.44M |
| Leases | 861.00K | 724.00K | 494.00K | 243.00K |
| OtherProperties | 2.36M | 1.47M | 1.55M | 1.08M |
| MachineryFurnitureEquipment | 3.83M | 2.38M | 2.33M | 2.12M |
| CurrentAssets | 40.52M | 44.16M | 21.33M | 37.09M |
| PrepaidAssets | 1.06M | 578.00K | 655.00K | 522.00K |
| Inventory | 2.57M | 2.11M | 1.62M | 1.14M |
| FinishedGoods | 18.00K | 210.00K | 179.00K | 92.00K |
| WorkInProcess | 638.00K | 562.00K | 510.00K | 436.00K |
| RawMaterials | 1.91M | 1.33M | 932.00K | 615.00K |
| Receivables | 2.25M | 2.45M | 1.25M | 1.39M |
| OtherReceivables | 682.00K | 648.00K | 213.00K | 165.00K |
| AccountsReceivable | 1.57M | 1.80M | 1.03M | 1.22M |
| CashCashEquivalentsAndShortTermInvestments | 34.64M | 39.02M | 17.80M | 34.04M |
| OtherShortTermInvestments | 15.72M | 29.38M | 13.17M | 22.04M |
| CashAndCashEquivalents | 18.92M | 9.64M | 4.63M | 12.00M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -23.27M | -16.76M | -16.02M | -13.55M |
| IssuanceOfCapitalStock | 1.60M | 37.53M | 0.00 | 35.03M |
| CapitalExpenditure | -1.40M | -381.00K | -473.00K | -344.00K |
| EndCashPosition | 18.92M | 9.64M | 4.63M | 12.00M |
| BeginningCashPosition | 9.64M | 4.63M | 12.00M | 12.64M |
| EffectOfExchangeRateChanges | 51.00K | -58.00K | -131.00K | -8.00K |
| ChangesInCash | 9.22M | 5.07M | -7.24M | -633.00K |
| FinancingCashFlow | 18.45M | 37.53M | -140.00K | 35.03M |
| CashFlowFromContinuingFinancingActivities | 18.45M | 37.53M | -140.00K | 35.03M |
| NetOtherFinancingCharges | -140.00K | |||
| ProceedsFromStockOptionExercised | 16.85M | 0.00 | ||
| NetCommonStockIssuance | 1.60M | 37.53M | 0.00 | 35.03M |
| CommonStockIssuance | 1.60M | 37.53M | 0.00 | 35.03M |
| InvestingCashFlow | 12.64M | -16.09M | 8.44M | -22.46M |
| CashFlowFromContinuingInvestingActivities | 12.64M | -16.09M | 8.44M | -22.46M |
| NetOtherInvestingChanges | -87.00K | -79.00K | -86.00K | -113.00K |
| NetInvestmentPurchaseAndSale | 14.13M | -15.64M | 9.00M | -22.00M |
| SaleOfInvestment | 29.00M | 24.50M | 28.00M | 2.00M |
| PurchaseOfInvestment | -14.87M | -40.14M | -19.00M | -24.00M |
| NetPPEPurchaseAndSale | -1.40M | -369.00K | -473.00K | -344.00K |
| SaleOfPPE | 0.00 | 12.00K | 0.00 | 0.00 |
| PurchaseOfPPE | -1.40M | -381.00K | -473.00K | -344.00K |
| OperatingCashFlow | -21.87M | -16.38M | -15.54M | -13.21M |
| CashFlowFromContinuingOperatingActivities | -21.87M | -16.38M | -15.54M | -13.21M |
| ChangeInWorkingCapital | 736.00K | -801.00K | 395.00K | -61.00K |
| ChangeInOtherWorkingCapital | -14.00K | |||
| ChangeInPayablesAndAccruedExpense | 1.48M | 812.00K | 724.00K | 622.00K |
| ChangeInPayable | 1.48M | 812.00K | 724.00K | 622.00K |
| ChangeInAccountPayable | 315.00K | 280.00K | -234.00K | 657.00K |
| ChangeInPrepaidAssets | -482.00K | 77.00K | 7.00K | -188.00K |
| ChangeInInventory | -464.00K | -485.00K | -478.00K | 272.00K |
| ChangeInReceivables | 198.00K | -1.21M | 142.00K | -767.00K |
| ChangesInAccountReceivables | 232.00K | -770.00K | 190.00K | -748.00K |
| OtherNonCashItems | -195.00K | 291.00K | -64.00K | -42.00K |
| StockBasedCompensation | 10.14M | 4.49M | 2.35M | 1.58M |
| UnrealizedGainLossOnInvestmentSecurities | -894.00K | -739.00K | 0.00 | |
| DepreciationAmortizationDepletion | 280.00K | 232.00K | 188.00K | 161.00K |
| DepreciationAndAmortization | 280.00K | 232.00K | 188.00K | 161.00K |
| Depreciation | 280.00K | 232.00K | ||
| OperatingGainsLosses | 72.00K | 67.00K | 78.00K | 74.00K |
| PensionAndEmployeeBenefitExpense | 72.00K | 73.00K | 78.00K | 75.00K |
| GainLossOnSaleOfPPE | 0.00 | -6.00K | 0.00 | -1.00K |
| NetIncomeFromContinuingOperations | -32.01M | -19.92M | -18.49M | -14.92M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NSPR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|